Enteric Bioengineering

Oral & Enteric Formulations

How advanced excipients, arginate stabilization, and absorption enhancers enable therapeutic peptides to survive gastric acid and digestive enzymes.

Gastric Degradation Notice

Standard unmodified peptides cannot be ingested orally, as gastric hydrochloric acid and pepsin break peptide bonds immediately. Only specifically engineered formulations (e.g. BPC-157 arginate salt or SNAC carriers) retain biological activity.

Engineering Oral Peptide Bioavailability

Two primary breakthrough technologies currently exist for oral administration:

Arginate Salt Stabilization (BPC-157)

Chemiosmotic binding with L-arginine protects the 15-amino acid chain from low pH degradation, allowing prolonged localized residence time in the gastric mucosa and small intestine.

SNAC Carrier Technology (Oral Semaglutide)

Sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) causes a localized pH increase in the stomach, neutralizing pepsin while transiently fluidizing gastric membranes to facilitate transcellular absorption.